Head-to-head evidence
JMKX000623 vs VX-993
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Diabetic Peripheral Neuropathic Pain
Shared mechanism: Voltage-gated sodium channel NaV1.8 · full Diabetic Peripheral Neuropathic Pain pipeline
JMKX000623
Developed by Jemincare
NCT06221241 · Phase 2 · status unknown
This randomized, quadruple-blind, placebo- and active-comparator-controlled phase 2 trial in 220 people with diabetic peripheral neuropathic pain is designed to compare change in average daily pain score against placebo over 12 weeks. Results have not yet been posted.
VX-993
Developed by Vertex Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT06619860 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JMKX000623's landscape · VX-993's landscape